Takeda Pharma announced decent results and an upward revision for the full year. On an accounting basis, the revision is big. On a real basis, less so, but still good. Then there's a ¥100bn buyback.
What is covered in the Full Insight:
Introduction
Takeda's Q3 Results and Revised Guidance
Share Buyback Announcement
Stock Performance and Valuation
Conclusion and Trading Considerations
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.